- Home
- CTMX
as 05-20-2024 4:00pm EST
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 147.3M | IPO Year: | 2015 |
| Target Price: | $6.53 | AVG Volume (30 days): | 6.7M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.04 - $5.85 | Next Earning Date: | 05-08-2024 |
| Revenue: | $119,178,000 | Revenue Growth: | 76.24% |
| Revenue Growth (this year): | -8.75% | Revenue Growth (next year): | -14.43% |
Share on Social Networks:
Stock Insider Trading Activity of CytomX Therapeutics Inc. (CTMX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ROWLAND LLOYD A | CTMX | General Counsel | Mar 19 '24 | Sell | $2.09 | 5,268 | $10,986.41 | 117,728 | SEC Form 4 |
| McCarthy Sean A. | CTMX | CEO | Mar 19 '24 | Sell | $2.09 | 20,223 | $42,175.07 | 524,481 | SEC Form 4 |
| BELVIN MARCIA | CTMX | SVP, Chief Scientific Officer | Mar 19 '24 | Sell | $2.09 | 12,795 | $26,683.97 | 168,579 | SEC Form 4 |
| Landau Jeffrey B | CTMX | Chief Business Officer | Mar 19 '24 | Sell | $2.09 | 6,562 | $13,685.05 | 110,060 | SEC Form 4 |
| BELVIN MARCIA | CTMX | SVP, Chief Scientific Officer | Dec 20 '23 | Sell | $1.38 | 4,077 | $5,628.30 | 155,124 | SEC Form 4 |
| McCarthy Sean A. | CTMX | CEO | Dec 20 '23 | Sell | $1.38 | 13,551 | $18,709.87 | 454,704 | SEC Form 4 |
Latest CytomX Therapeutics Inc. News
CTMX Breaking Stock News: Dive into CTMX Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
CytomX Therapeutics Announces New Employment Inducement Grants
Insider Monkey
11 days ago
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript
MT Newswires
11 days ago
BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating
Thomson Reuters StreetEvents
11 days ago
Q1 2024 CytomX Therapeutics Inc Earnings Call
MT Newswires
11 days ago
Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3
GuruFocus.com
12 days ago
CytomX Therapeutics Inc (CTMX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Associated Press Finance
12 days ago
CytomX Therapeutics: Q1 Earnings Snapshot
GlobeNewswire
12 days ago